• Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses. 

  Poudel, P; Nyamundanda, G; Patil, Y; Cheang, MCU; Sadanandam, A

  Breast cancer is a highly heterogeneous disease. Although differences between intrinsic breast cancer subtypes have been well studied, heterogeneity within each subtype, especially luminal-A cancers, requires further ...
• Standard and hypofractionated dose escalation to intraprostatic tumour nodules in localised prostate cancer: efficacy and toxicity in the DELINEATE trial. 

  Murray, JR; Tree, AC; Alexander, E; Sohaib, A; Hazell, S; Thomas, K; Gunapala, R; Parker, C; Huddart, R; Gao, A; Truelove, L; McNair, H; Blasiak-Wal, I; deSouza, NM; Dearnaley, D (2019-12-05)

  PURPOSE: To report a planned analysis of the efficacy and toxicity of dose escalation to the intraprostatic dominant nodule identified on multiparametric MRI (mp-MRI) using standard and hypofractionated external beam ...
• ISBN 978-3-030-11391-9 

  Else, M; Catovsky, D (Springer, 2019-03-01)
• Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials 

  Wojdacz, TK; Amarasinghe, HE; Kadalayil, L; Beattie, A; Forster, J; Blakemore, SJ; Parker, H; Bryant, D; Larrayoz, M; Clifford, R; Robbe, P; Davis, ZA; Else, M; Howard, DR; Stamatopoulos, B; Steele, AJ; Rosenquist, R; Collins, A; Pettitt, AR; Hillmen, P; Plass, C; Schuh, A; Catovsky, D; Oscier, DG; Rose-Zerilli, MJJ; Oakes, CC; Strefford, JC (American Society of Hematology, 2019-08-27)

  <jats:title>Key Points</jats:title> <jats:p>DNA methylation signatures can be used to divide IGHV-mutated CLL into clinically relevant subgroups. The memory-like DNA methylation subgroup is an independent marker of prolonged ...
• The Impacts of Bladder Cancer on UK Healthcare Costs and Patients’ Health-Related Quality of Life: Evidence from the BOXIT Trial 

  Hall, E; Porta, N
• Identifying Biomarkers to Pair with Targeting Treatments within Triple Negative Breast Cancer for Improved Patient Stratification. 

  Tovey, H; Cheang, MCU (2019-11-25)

  The concept of precision medicine has been around for many years and recent advances in high-throughput sequencing techniques are enabling this to become reality. Within the field of breast cancer, a number of signatures ...
• Evaluating a digital tool for supporting breast cancer patients: a randomised controlled trial protocol (ADAPT) 

  Husson, O; Lidington, E; McGrath, S; Noble, J; Stanway, S; Mohammed, K; van der Graaf, W
• Biomarker-guided trials: Challenges in practice. 

  Antoniou, M; Kolamunnage-Dona, R; Wason, J; Bathia, R; Billingham, C; Bliss, JM; Brown, LC; Gillman, A; Paul, J; Jorgensen, AL (2019-12)

  Biomarker-guided trials have drawn considerable attention as they promise to lead to improvements in the benefit-risk ratio of treatments and enhanced opportunities for drug development. A variety of such designs have been ...
• Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model. 

  Richartz, N; Duthil, E; Ford, A; Naderi, EH; Bhagwat, S; Gilljam, KM; Burman, MM; Ruud, E; Blomhoff, HK; Skah, S (2019-11-12)

  Acute lymphoblastic leukemia (ALL) develops in the bone marrow in the vicinity of stromal cells known to promote tumor development and treatment resistance. We previously showed that the cyclooxygenase (COX) inhibitor ...
• The Role of MicroRNA in Paediatric Acute Lymphoblastic Leukaemia: Challenges for Diagnosis and Therapy. 

  Grobbelaar, C; Ford, AM

  Acute lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Although the overall survival of children with ALL is now more than 90%, leukaemia remains one of the leading causes of death from disease. In ...
• Patient reported quality of life outcomes in patients treated for muscle invasive bladder cancer with radiotherapy +/- chemotherapy in the BC2001 phase III randomised controlled trial 

  Hall, E; Huddart, R; Lewis, R; Porta, N
• Planar Minimization Diagrams via Subdivision with Applications to Anisotropic Voronoi Diagrams 

  Bennett, H; Papadopoulou, E; Yap, C (2016-08)
• Examining the sources of occupational stress in an emergency department. 

  Basu, S; Yap, C; Mason, S (2016-12)

  BACKGROUND: Previous work has established that health care staff, in particular emergency department (ED) personnel, experience significant occupational stress but the underlying stressors have not been well quantified. ...
• Implementing the EffTox dose-finding design in the Matchpoint trial. 

  Brock, K; Billingham, L; Copland, M; Siddique, S; Sirovica, M; Yap, C (2017-07-20)

  BACKGROUND: The Matchpoint trial aims to identify the optimal dose of ponatinib to give with conventional chemotherapy consisting of fludarabine, cytarabine and idarubicin to chronic myeloid leukaemia patients in blastic ...
• Embracing model-based designs for dose-finding trials. 

  Love, SB; Brown, S; Weir, CJ; Harbron, C; Yap, C; Gaschler-Markefski, B; Matcham, J; Caffrey, L; McKevitt, C; Clive, S; Craddock, C; Spicer, J; Cornelius, V (2017-07-25)

  BACKGROUND: Dose-finding trials are essential to drug development as they establish recommended doses for later-phase testing. We aim to motivate wider use of model-based designs for dose finding, such as the continual ...
• Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. 

  Harrison, CN; Mead, AJ; Panchal, A; Fox, S; Yap, C; Gbandi, E; Houlton, A; Alimam, S; Ewing, J; Wood, M; Chen, F; Coppell, J; Panoskaltsis, N; Knapper, S; Ali, S; Hamblin, A; Scherber, R; Dueck, AC; Cross, NCP; Mesa, R; McMullin, MF (2017-10-26)

  Treatments for high-risk essential thrombocythemia (ET) address thrombocytosis, disease-related symptoms, as well as risks of thrombosis, hemorrhage, transformation to myelofibrosis, and leukemia. Patients resistant/intolerant ...
• Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study protocol for an open-label, non-randomised, prospective, single-arm trial. 

  Laing, RW; Mergental, H; Yap, C; Kirkham, A; Whilku, M; Barton, D; Curbishley, S; Boteon, YL; Neil, DA; Hübscher, SG; Perera, MTPR; Muiesan, P; Isaac, J; Roberts, KJ; Cilliers, H; Afford, SC; Mirza, DF (2017-11-28)

  INTRODUCTION: The use of marginal or extended criteria donor livers is increasing. These organs carry a greater risk of initial dysfunction and early failure, as well as inferior long-term outcomes. As such, many are ...
• Dose Transition Pathways: The Missing Link Between Complex Dose-Finding Designs and Simple Decision-Making. 

  Yap, C; Billingham, LJ; Cheung, YK; Craddock, C; O'Quigley, J (2017-12-15)

  The ever-increasing pace of development of novel therapies mandates efficient methodologies for assessment of their tolerability and activity. Evidence increasingly support the merits of model-based dose-finding designs ...
• Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. 

  Newsome, PN; Fox, R; King, AL; Barton, D; Than, N-N; Moore, J; Corbett, C; Townsend, S; Thomas, J; Guo, K; Hull, D; Beard, HA; Thompson, J; Atkinson, A; Bienek, C; McGowan, N; Guha, N; Campbell, J; Hollyman, D; Stocken, D; Yap, C; Forbes, SJ (2018-01)

  BACKGROUND: Results of small-scale studies have suggested that stem-cell therapy is safe and effective in patients with liver cirrhosis, but no adequately powered randomised controlled trials have been done. We assessed ...
• Adaptive designs in clinical trials: why use them, and how to run and report them. 

  Pallmann, P; Bedding, AW; Choodari-Oskooei, B; Dimairo, M; Flight, L; Hampson, LV; Holmes, J; Mander, AP; Odondi, L; Sydes, MR; Villar, SS; Wason, JMS; Weir, CJ; Wheeler, GM; Yap, C; Jaki, T (2018-02-28)

  Adaptive designs can make clinical trials more flexible by utilising results accumulating in the trial to modify the trial's course in accordance with pre-specified rules. Trials with an adaptive design are often more ...

View more